Premenstrual Syndrome Treatment Market is Expected to Reach $1,829 Million by 2031 - AG, Eli Lilly And Company, GlaxoSmithKline Plc., H. Lundbeck A/S

𝗧𝗵𝗲 𝗣𝗿𝗲𝗺𝗲𝗻𝘀𝘁𝗿𝘂𝗮𝗹 𝗦𝘆𝗻𝗱𝗿𝗼𝗺𝗲 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗠𝗮𝗿𝗸𝗲𝘁 𝘄𝗮𝘀 𝘃𝗮𝗹𝘂𝗲𝗱 𝗮𝘁 𝗨𝗦𝗗 𝟭,𝟯𝟲𝟳 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝟮𝟬𝟮𝟮 𝗮𝗻𝗱 𝗶𝘀 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝗲𝗱 𝘁𝗼 𝗿𝗲𝗮𝗰𝗵 𝗨𝗦𝗗 𝟭,𝟴𝟮𝟵 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟯𝟭, 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 𝗮𝘁 𝗮 𝗰𝗼𝗺𝗽𝗼𝘂𝗻𝗱 𝗮𝗻𝗻𝘂𝗮𝗹 𝗴𝗿𝗼𝘄𝘁𝗵 𝗿𝗮𝘁𝗲 (𝗖𝗔𝗚𝗥) 𝗼𝗳 𝟰.𝟭% 𝗱𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗳𝗼𝗿𝗲𝗰𝗮𝘀𝘁 𝗽𝗲𝗿𝗶𝗼𝗱 𝗳𝗿𝗼𝗺 𝟮𝟬𝟮𝟰 𝘁𝗼 𝟮𝟬𝟯𝟭.

Premenstrual Syndrome (PMS) is characterized by a combination of physical and emotional symptoms such as mood swings, body aches, fatigue, tender breasts, food cravings, irritability, and depression. These symptoms typically appear toward the end of the luteal phase and subside with the onset or shortly afterward. PMS is most commonly observed in women experiencing high levels of stress, depression, hormonal fluctuations during the menstrual cycle, and chemical changes in the brain.

𝗚𝗲𝘁 𝗮 𝗙𝗿𝗲𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗣𝗗𝗙 - https://www.datamintelligence.com/download-sample/premenstrual-syndrome-treatment-market

𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬:
The global premenstrual syndrome (PMS) treatment market is expanding due to several key factors, including increased awareness of the importance of PMS treatment and growing initiatives by governments and non-governmental organizations to support women's healthcare. Additionally, advancements in new therapies are contributing to market growth.

A large target population further drives the market, as PMS is a common health issue among women of reproductive age. According to a study by Petranka Chumpalova et al. (2020) published in the Annals of General Psychiatry, around 90% of women of reproductive age experience some premenstrual symptoms, with 20-40% suffering from PMS and 2-8% experiencing premenstrual dysphoric disorder (PMDD) globally.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀

By Drug Class: Analgesics, Antidepressants, Oral Contraceptives, Ovarian Suppression Agents, Gonadotropin-releasing hormone (GnRH) Analogues, Estrogen-only patches & implants, Selective serotonin reuptake inhibitors (SSRIs), Others

By Distribution Channel: Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers, Others

𝗚𝗲𝘁 𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝘁𝗵𝗲 𝗿𝗲𝗽𝗼𝗿𝘁 𝗮𝘀 𝗽𝗲𝗿 𝘆𝗼𝘂𝗿 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀 - https://www.datamintelligence.com/customize/premenstrual-syndrome-treatment-market

𝗠𝗮𝗷𝗼𝗿 𝗞𝗲𝘆 𝗽𝗹𝗮𝘆𝗲𝗿𝘀
• Bayer AG
• Eli Lilly And Company
• GlaxoSmithKline Plc.
• H. Lundbeck A/S
• Pfizer Inc.
• Asarina Pharma AB
• Chattem, Inc. (Sanofi)
• Dekk-Tec
• Pherin Pharmaceuticals
• Novartis International AG

* 𝗡𝗼𝘁𝗲:

Additionally, I wanted to highlight that the full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted.

𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀

The global Premenstrual Syndrome Treatment Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

The global Premenstrual Syndrome Treatment Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Silicone Pin Mat Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.

Related Reports:

Chronic Disease Management Market: https://www.datamintelligence.com/research-report/chronic-disease-management-market

Pain Management Devices Market: https://www.datamintelligence.com/research-report/pain-management-devices-market

Affiliate Marketing Request here: https://www.datamintelligence.com/affiliate-marketing

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.